Asia Pacific Cell & Gene Research: Novotech is Growing 50% Faster than ROW ACN Newswire

Asia Pacific Cell & Gene Research: Novotech is Growing 50% Faster than ROW

February 3, 2023
SYDNEY, AU, Feb 3, 2023 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW. The majority of trials are in oncology, specifically for blood cancers, viral infections, and solid tumors.Novotech, which has extensive experience in cell & gene therapy clinical trials, is sponsoring the 6th Annual Cell And Gene Therapy Innovation Summit in Berlin, Germany (15-16 February 2023).The company recently acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech's global expansion program in Europe and the US.The acquisition means biotech clients can access Novotech's unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. The latest data shows Asia Pacific is the fastest-growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies, with China leading in the region.The region already accounts for over a third of cell & gene therapy trial activity and shows a nearly 50% faster growth rate in cell & gene therapy trials compared to ROW between 2016 and 2021. China shows a 15% faster growth rate than the ROW. After oncology, the majority of cell & gene trials are in infectious diseases, CNS, and cardiovascular diseases.In addition, the Asia Pacific is the leading location globally for CAR-T trials with China attracting ~60% of all CAR-T trials globally between 2015-2022.Novotech CEO Dr. John Moller said: "Cell & gene therapy research typically presents another level of complexity and regulatory processes which means an experienced CRO partner is vital. Our deep experience, exceptional site and investigator relationships - which also translates to patent access - our project management approach focused on problem-solving, ownership and flexibility, and our investments in data and technology combine to deliver the service biotechs need in this specialist sector for success."Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, selected for the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed 45 Leading Site Partnership agreements over the last 3 years.Download our latest data report:Evolution of Clinical Trials in the Asia Pacific Region Compared to the US and the EU5https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5About Novotech (Novotech-CRO.com)Novotech is internationally recognized as the leading Asia Pacific centred biotech Contract Research Organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 2,700 staff working across offices in 20 geographies. For more information visit https://novotech-cro.com/contactMedia ContactDavid Jamescommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
SinoHytec Successfully Listed on the Main Board of HKEX ACN Newswire

SinoHytec Successfully Listed on the Main Board of HKEX

January 12, 2023
HONG KONG, Jan 12, 2023 - (ACN Newswire via SEAPRWire.com) - The leading provider of fuel cell systems in China - Beijing SinoHytec Co., Ltd. ("SinoHytec" or the "Company", Stock Code: 2402), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange" or "HKEX") today, under the stock code of 2402 and the Offer Price is HK$60 per Share in board lots of 50 shares each.SinoHytec is listed on the main board of HKEX, with 17,628,000 shares being offered globally, Among them, the International Offering was moderately over-subscribed, representing approximately 1.84 times the total number of 15,865,200 Offer Shares initially available under the International Offering.The Hong Kong Public Offering was slightly over-subscribed, representing approximately 0.29 times the total number of 1,762,800 Offer Shares initially available for subscription under the Hong Kong Public Offering.The net proceeds from the Global Offering to be received by the Company is estimated to be approximately HK$982.8million, after deduction of the underwriting commissions, fees and other estimated expenses payable in connection with the Global Offering, of which approximately 75% of the net proceeds received from the Global Offering will be used to fund the Company's research and development in the next three years; and about 15% will be used to enhance the Company's brand recognition through product promotion and multi-channel marketing in the next three years; the remaining approximately 10.0% will be used for working capital and other general corporate purposes.SinoHytec adheres to the R&D principles of "Advance Research", "Continuous Development" and "In-depth Promotion". Following a vertically integrated R&D path, it has evolved from integrating the fuel cell system into the fuel cell powertrain assembly, to developing and manufacturing the fuel cell system and the stack, and most recently the bipolar plate (the core component of the stack). In addition, the Company plans to develop and manufacture membrane electrodes, another major fuel cell stack component, through its main associate company, Shanghai Maximfuelcell Technology Co., Ltd.In addition to independent research and development, the Company jointly undertakes research and development projects and jointly develops fuel cell vehicles with research institutions, government departments and well-known automobile manufacturers. The Company's industry competitive advantages derive from its continuous leading position in the fast-growing Chinese fuel cell system market, strong R&D strength, established stable cooperative relations with domestic mainstream commercial vehicle companies, integrated parts supply system and established in-depth cooperation relations with suppliers, as well as the support of experienced senior management team and high-quality staff team, which will help the Company stand out from its many opponents.Mr. Zhang Guoqiang, Chairman, Executive Director and General Manager of SinoHytec said: "Today, SinoHytec is officially listed on the Main Board of the Hong Kong Stock Exchange, which is an important milestone in the Company's development and marks the entry of SinoHytec into the international capital market. We would like to express our gratitude to our investors for their trust and support of SinoHytec. Setting off from a new starting point, we will further promote the research and development of fuel cell systems and core components; Expand the production capacity of fuel cell stacks to meet the growing market demand and achieve economies of scale; economies of scale; strategically expand customer base and regional coverage; expand and strengthen the supply chain; and enhance brand awareness and promote the application of fuel cell systems. We will grasp the future trends and directions of the industry, and leverage our own competitive advantages to further consolidate SinoHytec's market position to create the greatest value for shareholders and investors." Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
SinoHytec Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange, Offer Price Between HK$60 and HK$76 per H Share, Raise up to HK$1,540.7 million ACN Newswire

SinoHytec Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange, Offer Price Between HK$60 and HK$76 per H Share, Raise up to HK$1,540.7 million

December 29, 2022
HONG KONG, Dec 29, 2022 - (ACN Newswire via SEAPRWire.com) - The leading provider of fuel cell systems in China - Beijing SinoHytec Co., Ltd. ("SinoHytec" or the "Company", Stock Code: 2402), today announced the proposed listing of its shares on the Main Board of the Stock Exchange of Hong Kong Limited ( the "Hong Kong Stock Exchange"). SinoHytec plans to offer an aggregate of 17,628,000 H shares under the Global Offering (subject to the Over-allotment Option), comprising an International Offering of 15,865,200 H shares (subject to Reallocation and the Over-allotment Option), representing 90% of the initial offer shares; and Hong Kong Public Offering of 1,762,800 H shares (subject to Reallocation), representing 10% of the initial offer shares), at a price range between HK$60 and HK$76 per Offer Share. The Hong Kong Public Offering will commence at 9 a.m., December 29, 2022 (Thursday), and close at 12:00 noon on January 5, 2023 (Thursday). Dealings in the shares of SinoHytec on the Main Board of the Hong Kong Stock Exchange is expected to commence on January 12, 2023 (Thursday), with the stock code 2402 and in board lots of 50 Offer Shares each.Guotai Junan Capital Limited and Giraffe Capital Limited are the Joint Sponsors.SinoHytec is a leading provider of fuel cell systems in China, focusing on the design, development and manufacture of fuel cell systems and stacks (a key component of the system) mainly for commercial vehicles, such as buses and trucks. According to the China Insights Industry Consultancy Limited Report ("CIC Report"), the company ranked first in the PRC fuel cell system market in terms of the total power output of fuel cell systems sold* in 2021, with a market share of 27.8%; and in 2021, fuel cell systems accounted for approximately 0.8% of the total sales volume of new energy systems for commercial vehicles, while lithium battery systems accounted for the rest of the total sales volume. As of June 30, 2022, the company's fuel cell systems were installed on 80 models of fuel cell vehicles that are featured in the MIIT New Energy Vehicle Catalogs, ranking us first in the industry.Leader in China's fast growing fuel cell system marketEstablished in 2012, the company is a pioneer in the R&D and commercialization of fuel cell systems in China and started batch production in 2016. The company also participated in the fuel cell vehicle development and commercialization scheme of the United Nations Development Programme in China and witnessed the progress of the PRC fuel cell industry from the R&D phase to pilot testing and to commercialization. The company's fuel cell systems are installed on commercial vehicles operating across various PRC cities, including Beijing, Zhangjiakou, Shanghai, Chengdu, Zhengzhou and Zibo. As of December 20, 2022, the company's fuel cell systems have powered over 2,800 fuel cell vehicles on the road in China. These vehicles had an average mileage of around 40,000 kilometers per vehicle, accumulating over 108.6 million kilometers and 2.3 million hours of operations, which built an industry leading record.Strong research and development capabilitiesThe Company adheres to a R&D principle of "Advance Research", "Continuous Development" and "In-depth Promotion". The key objectives of the Company R&D and product testing activities are to optimize and upgrade the company products' adverse weather capabilities, durability, reliability, efficiency, safety and economy. As of June 30, 2022, the Company has establised an outstanding R&D team of 270 members. The Company also cooperated with leading research universities in China, such as Tsinghua University, to facilitate the development and commercialization of innovative fuel cell technologies so that the Company can respond to the fast-changing market demands.The Company's R&D team has progressively developed the 30kW, 40kW, 50kW, 60kW, 80kW, 100kW, 120kW and 150kW models of fuel cell systems over the years. In particular, the Company launched the 240kW high power output model in December 2021, which is the first automotive fuel cell system in China that can reach a rated power of 240kW.In addition, the Company participated in and achieved significant results in various R&D projects sponsored by the PRC government. As of June 30, 2022, the Company had over 590 patents, including over 210 invention patents, over 360 utility model patents, and 20 design patents. In addition, the Company has more than 590 patent applications that have been accepted by the State Intellectual Property Office of China.* Sales volume of fuel cell systems comprises only direct sales to fuel cell vehicle manufacturers.Solid partnerships with major PRC commercial vehicle manufacturersThe Company has built solid long-term partnerships with major commercial vehicle manufacturers in China, such as Beiqi Foton, Yutong Bus and Geely Commercial Buses, through jointly undertaking national-level R&D projects and codeveloping, demonstrating and testing fuel cell vehicles. In particular, Beiqi Foton and Yutong Bus purchased the Company's fuel cell systems on order basis since 2016 and 2018, respectively, for the production of their fuel cell vehicles. The Company codeveloped with Toyota and Beiqi Foton transit buses using the Company's fuel cell systems which are designated as the official transport vehicles at the Beijing 2022 Olympic Winter Games. As of June 30, 2022, the Company has sold fuel cell systems to over 20 commercial vehicle manufacturers whose total fuel cell vehicles sold in 2021 represented nearly 60% of the market share in China. In addition, Beiqi Group and Yutong Bus have become the company Shareholders and strategic partners, representing the recognition of us by the downstream players of the fuel cell vehicle industry.Integrated components supply system and close cooperation with suppliersAfter years of dedication, the Company built a comprehensive procurement system with local suppliers. During the Track Record Period, the Company has established a relatively stable long-term relationship with over 300 suppliers in China, providing parts such as MEA and air compressors. During the Track Record Period, the company had localized the supply of MEA and procured more raw materials from local suppliers each year.Mr. Zhang Guoqiang, Chairman, Executive Director and General Manager of SinoHytec said, "Our mission is to leverage advanced hydrogen fuel cell technologies to contribute to China's carbon emission peak and carbon neutralitygoal and empower global energy transition. We are committed to becoming a global leader in hydrogen fuel cell technologies for promoting a sustainable and low-carbon future. New energy vehicle development is strategically significant to China's energy security and environmental protections. We intend to achieve this goal by implementing the following strategies: further advance the R&D of fuel cell systems and core components; expand the production capacity of fuel cell stacks to meet the growing market demand and achieve economies of scale; strategically expand our customer base and geographical coverage; expand and strengthen our supply chains; and improve our brand awareness and promote the application of fuel cell systems. We will grasp the opportunities arising in future trend and development of the industry, leverage on our competitive advantages to further consolidate SinoHytec's market position, and create the greatest value for shareholders and investors."Beijing SinoHytec Co., Ltd.Fact SheetInformation on the Global Offering:Number of Offer Shares under the Global Offering: 17,628,000 H Shares (subject to the Over-allotment Option)Number of Hong Kong Offer Shares: 1,762,800 H Shares (subject to reallocation)Number of International Offer Shares: 15,865,200 H Shares (subject to reallocation and the Over-allotment Option)Maximum Offer Price: HK$76.00 per H Share, plus brokerage fee of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong dollars and to refund)Board Lot: 50 H SharesStart of the Hong Kong Public Offering: 9:00 a.m., December 29, 2022 (Thursday)End of the Hong Kong Public Offering: 12:00 noon, January 5, 2023 (Thursday)Announcement of Allotment Results: January 11, 2023 (Wedsnesday)Expected Listing Date: January 12, 2023 (Thursday)Stock Code: 2402Use of Proceeds:The Company estimates that it will receive net proceeds of approximately HK$1121.8 million from the Global Offering, after deducting the underwriting commissions, fees and estimated expenses payable by the Company in connection with the Global Offering, assuming that the Over-allotment Option is not exercised and assuming an Offer Price of HK$68 per Share (being the mid-point of the indicative Offer Price range). The Company intends to use the net proceeds for the following purposes: 1) Approximately 75.0% (approximately HK$841.2 million) will be used to fund the research and development in the next three years;2) Approximately 15.0% (approximately HK$168.4 million) will be used for improving the brand recognition through product promotion and multi-channel marketing in the next three years; 3) Approximately 10.0% (approximately HK$112.2 million) will be used for working capital and other general corporate purposes. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Sees Rise in Profit Margins for 1Q ACN Newswire

Malaysian Genomics Sees Rise in Profit Margins for 1Q

November 23, 2022
PETALING JAYA, Malaysia, Nov 23, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today reported a revenue of RM3.81 million for the first quarter ended 30 September 2022 (1Q 2023) versus a revenue of RM9.32 million in 1Q 2022, as the Group refocuses on immunotherapy and cell therapies under the biopharmaceutical business and pushes for organic growth of its genetic screening business.Independent Non-Executive Chairman, Dato' Seri Dr Chen Chaw MinThe Group recorded a 254.16% increase in profit before tax (PBT) to RM0.85 million for 1Q 2023, compared with RM0.24 million in the corresponding quarter of the previous financial year, on higher profit margins and revenue contributions from the new biopharmaceutical business.Earnings per share for 1Q 2023 stood at 0.68 sen compared with 0.20 sen in 1Q 2022.Dato' Seri Dr Chen Chaw Min, Independent Non-Executive Chairman of Malaysian Genomics said, "The Group's pivot to immunotherapy and cell therapies from vaccine distribution continues to pay off as PBT improves on higher profit margins. We expect more improvements to the biopharmaceutical business as the Group's expansion of its distribution network and footprint overseas in the Middle East and Southeast Asia takes shape.""We are pushing the genetic screening business as the Group continues to reach out through business-to-consumer channels for a wider market reach. We believe better awareness and education is prompting more people to take action on how they can enhance their health, and the Group will leverage on this through catering to the different needs and groups from our suite of healthcare-related solutions. We are also seeking to acquire assets or invest in businesses that will support the expanded market reach of our products and services.""The Group is well positioned to be a leading provider of genetic screening, genome analysis, and biopharmaceutical products in Southeast Asia, as we are equipped with a high-throughput sequencing lab, an advanced microarray facility, and a new state-of-the-art cGMP cell processing lab for cell therapies, including immunotherapy for various types of cancers. We are confident that we are in a position to provide patients with better access to the latest precision and personalised healthcare solutions."Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference ACN Newswire

Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference

September 15, 2022
SYDNEY, AU, Sep 15, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Cell & Gene Therapy Clinical Trials award at the 6th Cell & Gene Therapy World Asia 2022 conference.Novotech has extensive experience in cell & gene therapy clinical trials across Asia Pacific. The Asia Pacific accounts for over a third of cell & gene therapy trial activity with China being the leading location in APAC. In addition, APAC has nearly a 50% faster growth rate in cell & gene therapy trials than ROW. Blood cancers (ALL, NHL, DLBCL, lymphomas), solid tumors, viral infections, liver and gastrointestinal tract cancers are the top indications in China-based cell & gene therapy trials between 2016 and 2021.Watch our recent Endpoints News webinar for more information:EVOLUTION OF CELL & GENE THERAPY IN CHINA: THE CASE FOR UNIVERSAL CAR-Thttps://novotech-cro.com/webinars/evolution-cell-gene-therapy-china-case-universal-car-tThe award was presented to Novotech during the 6th Cell & Gene Therapy World Asia 2022 conference (14th - 15th September) at the Sheraton Towers, Singapore.Novotech CEO Dr. John Moller said, "We are extremely pleased our team has been recognized with this prestigious award at the 6th Cell & Gene Therapy World Asia 2022 conference. Cell & gene therapy is driving recent innovations in biotech and it is an honour to be recognized as the CRO at the forefront in Asia-Pacific supporting this vital clinical research. Cell & gene therapy research typically presents another level of complexity and regulatory processes which means an experienced CRO partner is vital. Our deep experience, exceptional site and investigator relationships - which also translates to patent access - our project management approach focused on problem-solving, ownership and flexibility, and our investments in data and technology combine to deliver the service biotechs need in this specialist sector for success."Novotech has recently also been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.Download our latest data reports here:EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5About Novotech Novotech is the leading Asia-Pacific centered, globally capable, biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Forms Partnership for Expansion in Saudi Arabia ACN Newswire

Malaysian Genomics Forms Partnership for Expansion in Saudi Arabia

July 13, 2022
PETALING JAYA, Malaysia, Jul 13, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that it has entered into a strategic partnership with United Doctors Hospital (UDH) for collaboration in genomics and cell therapies.Azri Azerai, Executive Director of Malaysian GenomicsUDH, located in Jeddah, Saudi Arabia, is accredited by the Saudi Central Board for Accreditation of Healthcare Institutions. UDH has also won numerous awards for social responsibility, including the King Khalid Award for Social Responsibility in 2018, and is certified with the SA8000, the world's leading social certification programme, by Social Accountability International (formerly known as Social Accountability Accreditation Services), a United States-based charitable organisation, in 2016.Under the partnership, which is valid for three years, Malaysian Genomics and UDH will take the necessary steps to encourage and promote cooperation in the sales and marketing of genetic screening tests and cell therapy products; collaboration in research and development (R&D), and other areas of cooperation in the genomics and cell therapies to be mutually decided by both parties. Encik Azri Azerai, Executive Director of Malaysian Genomics, said, "This strategic partnership with UDH enables us to expand the geographical reach of our products and services beyond Malaysia to the Middle East and North Africa region. It will also enable us to collaborate on R&D with various domain specialists to enhance our suite of genetic screening tests and cell therapies."Dr. Hefny Moustafa Hefny, Medical Doctor at UDH, said, "Among the areas being explored by Malaysian Genomics and UDH are opportunities to develop genetic screening tests for hereditary conditions and diseases that are prevalent in the Middle East or Northern Africa, which may be different from other parts of the world."Malaysian Genomics is actively expanding its business-to-consumer channels as part of the Group's growth strategy. The Group recently acquired a 51% stake in kidney dialysis operator Aquahealth Sdn Bhd to offer personalised kidney care that also involves nutrition management, lifestyle changes, and genetic testing. It is also collaborating with AirAsia's Asean Super App online shopping platform and Speedoc to provide genetic screening services.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More